Introduction: Major depressive disorder (MDD) continues to be one of the highest contributors to disease burden and years lived with disability in the world. Current existing treatments have been associated with intolerable side effects, long onset of action and suboptimal remission rates. Newer agents are being developed that will be reviewed here, such as glutamate and gamma-aminobutyric acid (GABA) and the reinvigorated testing of psychedelic drugs. This review will summarize the target mechanisms of the newer ADTs currently in development and available on the market.
Areas Covered: It briefly covers the existing agents for MDD and treatment-resistant depression (TRD) and the need for new agents with higher efficacy. Therapeutic agents currently in Phase II or later clinical trials are listed and discussed, based on a thorough review of the US National Institutes of Health clinicaltrials.gov index and a search of the Informa Pharmaprojects database. Compounds of interest are grouped into scientific rationale and include atypical antipsychotics, GABA positive allosteric modulators, glutamatergic agents, opioids, orexin 2 receptor antagonists, and psychedelics.
Expert Opinion: New therapeutic agents currently in development are promising, with a more rapid onset of action and the ability to augment and treat TRD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14728214.2022.2117297 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized trial of virtual reality eye movement desensitization and reprocessing therapy for major depressive disorder with childhood trauma: A 3-month follow-up study.
Psychol Trauma
January 2025
Department of Psychiatry, First Affiliated Hospital of Jinan University.
Objective: Eye movement desensitization and reprocessing therapy (EMDR) is effective in treating major depressive disorder (MDD) with childhood trauma, and virtual reality (VR) can further extend its application form. However, the utilization of VR-EMDR in treating MDD with childhood trauma is still in its infancy, and whether it can improve depressive symptoms and traumatic experience remains unknown.
Method: Seventy-two MDD patients were randomly allocated to the intervention group and the wait-list control group on a 1:1 basis.
Mediators of a randomized controlled trial of a preventive intervention for youth of parents with depressive disorders.
J Consult Clin Psychol
January 2025
Department of Psychology and Human Development, Vanderbilt University.
Objective: The present study assessed two theory-driven mediators of the effects of a family group cognitive-behavioral (FGCB) preventive intervention for youth of parents with a history of major depressive disorder (MDD) or dysthymia on long-term youth psychopathology symptoms and diagnoses.
Method: Sample included 180 parents ( = 41.9, 89% female, 82% White, non-Hispanic) and one of their children/adolescents ages 9-15 years ( = 11.
The Challenging Problems of Cancer and Serious Mental Illness.
Curr Psychiatry Rep
January 2025
Institute of Psychiatry, Department of Neuroscience and Rehabilitation, University of Ferrara, Via Fossato di Mortara 64a, Ferrara, 44121, Italy.
PURPOSE OF REVIEW: Patients with Serious Mental Illness (SMI) are reported to be at higher risk for somatic disorders (e.g. cardiovascular and metabolic diseases) and higher mortality, compared to the general population, because of the consequences of SMI including psychotropic medication side effects, sedentary and unhealthy lifestyle, difficult access to physical health care.
View Article and Find Full Text PDFPatient-reported outcome measures to assess mental and physical health status, functionality, and quality of life in patients with major depression or schizophrenia.
J Patient Rep Outcomes
January 2025
Parc Sanitari Sant Joan de Déu, General Hospital, C/ Doctor Antoni Pujadas 42, Sant Boi de Llobregat, Barcelona, E-08830, Spain.
Background: Patient-reported outcomes measures (PROMs) are standardized self-administered tools that assess the patient's opinion on the level of health, quality of life, and disability among other aspects. The objective of this study was to gather information on physical and mental health in patients with major mental illness using PROMs.
Methods: This was an observational, naturalistic, prospective study carried out in adult stabilized outpatients attended at nine Adult Mental Health Centers in Barcelona, Spain.
Major Depressive Disorder and Driving Behavior Among Older Adults.
JAMA Netw Open
December 2024
Department of Psychiatry, Washington University in St Louis, St Louis, Missouri.
Importance: Depression and antidepressant use are independently associated with crash risk among older drivers. However, it is unclear what factors impact daily driving that increase safety risk for drivers with depression.
Objective: To examine differences in naturalistic driving behavior and safety between older adults with and without major depressive disorder (MDD).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!